Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2

PLoS Pathogens

Volumn 5, Issue 5, 2009, Pages

  Jia, Bin ^a   Serra Moreno, Ruth ^a   Neidermyer Jr , William ^a   Rahmberg, Andrew ^a   Mackey, John ^a   Fofana, Ismael Ben ^a   Johnson, Welkin E ^a   Westmoreland, Susan ^a   Evans, David T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; NEF PROTEIN; TETHERIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VPU PROTEIN; BST2 PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INTERFERON; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NEF PROTEIN, SIV; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ALLELE; AMINO ACID ANALYSIS; ARTICLE; CELL MEMBRANE; CELL SURFACE; CERCOCEBUS; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES DIFFERENCE; VIRUS GENE; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; GENETICS; MACACA; METABOLISM; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT;

CERCOCEBUS TORQUATUS ATYS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; CELL LINE; CERCOCEBUS ATYS; DOWN-REGULATION; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERONS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RETROVIRIDAE PROTEINS; SEQUENCE ALIGNMENT; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES SPECIFICITY; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 67249114758     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000429     Document Type: Article

References (90)

1. Neil SJD, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430. (Pubitemid 351158893)
2. VanDamme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral vpu protein. Cell Host Microbe 3: 1-8.
3. Strebel K, Klimkait T, Martin MA (1988) A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241: 1221-1223. (Pubitemid 18216003)
4. Strebel K, Klimkait T, Maldarelli F, Martin MA (1989) Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 63: 3784-3791. (Pubitemid 19205450)
5. Terwilliger EF, Cohen EA, Lu Y, Sodroski JG, Haseltine WA (1989) Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A 86: 5163-5167. (Pubitemid 19182254)
6. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM (1990) The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 64: 621-629. (Pubitemid 20032674)
7. Geraghty RJ, Talbot KJ, Callahan M, Harper W, Panganiban AT (1994) Cell type-dependence for Vpu function. J Med Primatol 23: 146-150.
8. Sakai H, Tokunaga K, Kawamura M, Adachi A (1995) Function of human immunodeficiency virus type 1 Vpu protein in various cell types. J Gen Virol 76: 2717-2722.
9. Neil SJD, Eastman SW, Jouvenet N, Bieniasz PD (2006) HIV-1 vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2: 354-367. doi:10.1371/journal.ppat.0020039. (Pubitemid 43794303)
10. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 100: 15154-15159. (Pubitemid 37518032)
11. Neil SJD, Sandrin V, Sundquist WI, Bieniasz PD (2007) An interferon-ainduced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 vpu protein. Cell Host Microbe 2: 193-203. (Pubitemid 47355204)
12. Bartee E, McCormack A, Fruh K (2006) Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2: 0975-0988. doi:10.1371/journal.ppat.0020107.
13. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, et al. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4: 694-709. (Pubitemid 37168591)
14. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G (2007) Clatharin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 120: 3850-13058 (Pubitemid 350187366)
15. Aloia RC, Jensen FC, Curtain CC, Mobley PW, Gordon LM (1988) Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A 85: 900-904. (Pubitemid 18073935)
16. Nguyen DH, Hildreth JEK (2000) Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 74: 3264-3272. (Pubitemid 30143751)
17. Ono A, Freed EO (2001) Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A 98: 13925-13930. (Pubitemid 33116000)
18. Scheiffele P, Rietveld A, Wilk T, Simons K (1999) Influenza viruses select ordered lipid domains during budding from the plasma membrane. J Biol Chem 274: 2038-2044. (Pubitemid 29061354)
19. Panchai RG, Ruthel G, Kenny TA, Kallstrom GH, Lane D, et al. (2003) In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A 100: 15936-15941.
20. Gottlinger HG (2008) Virus kept on a leash. Nature 451: 406-408.
21. Gao F, Bailes E, Roberstson DL, Chen Y, Rodenburg CM, et al. (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes. Nature 397: 436-441. (Pubitemid 29078911)
22. Courgnaud V, Salemi M, Pourrut X, Mpoudi-Ngole E, Abela B, et al. (2002) Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Ceropithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny. J Virol 76: 8298-8309. (Pubitemid 34809084)
23. Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, et al. (2003) Hybrid origin of SIV in chimpanzees. Science 300: 1713. (Pubitemid 36712560)
24. Courgnaud V, Abela B, Pourrut X, Mpoudi-Ngole E, Loul S, et al. (2003) Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different Cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol 77: 12523-12534. (Pubitemid 37430648)
25. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83: 2382-2385.
26. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106: 2886-2891.
27. Jouvenet N, Neil SJD, Zhadina M, Zang T, Kratovac Z, et al. (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83: 1837-1844.
28. Bour S, Schubert U, Peden K, Strebel K (1996) The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a vpu-like factor? J Virol 70: 820-829. (Pubitemid 26028997)
29. Ritter GD, Yamshchikov G, Cohen SJ, Mulligan MJ (1996) Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J Virol 70: 2669-2673. (Pubitemid 26087639)
30. Bour S, Akari H, Miyagi E, Strebel K (2003) Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 309: 85-98. (Pubitemid 36506592)
31. Abada P, Noble B, Cannon PM (2005) Functional domains within the human immunodeficiency virus type 2 envelope glycoprotein required to enhance virus production. J Virol 79: 3627-3638. (Pubitemid 40327951)
32. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR (1989) An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339: 389-392. (Pubitemid 19144229)
33. Chen Z, Telfer P, Gettie A, Reed P, Zhang L, et al. (1996) Genetic characterization of new West African simian immunodeficiency virus SIVsm: Geographic clustering of household-derived SIV strains with human immundeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop. J Virol 70: 3617-3627. (Pubitemid 26157342)
34. Murphey-Corb M, Martin LN, Rangan SRS, Baskin GB, Gormus BJ, et al. (1986) Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 321: 435-437. (Pubitemid 16055495)
35. Hahn BH, Shaw GM, Cock KMD, Sharp PM (2000) AIDS as a Zoonosis: Scientific and public health implications. Science 287: 607-614. (Pubitemid 30070900)
36. Mansfield KG, Lerch NW, Gardner MB, Lackner AA (1995) Origins of simian immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol 24: 116-122.
37. Sawyer SL, Emerman M, Malik HS (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2: 1278-1285. doi:10.1371/journal.pbio.0020275.
38. Sawyer SL, Wu LI, Emerman M, Malik HS (2005) Positive selection of primate TRIM5a identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA 102: 2832-2837. doi:10.1371/journal.pbio.0020275. (Pubitemid 40299877)
39. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) TRIM5a restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
40. Yap MW, Nicole S, Stoye JP (2005) A single amino acid in the SPRY domain of human TRIM5alpha leads to HIV-1 restriction. Curr Biol 15: 73-78. (Pubitemid 40084706)
41. Stremlau M, Perron M, Welikala S, Sodroski J (2005) Species-specific variation in the B30.2(SPRY) domain of TRIM5a determines the potency of human immunodeficiency virus restriction. J Virol 79: 3139-3145. (Pubitemid 40270592)
42. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, et al. (2005) Retrovirus restriction by TRIM5a variants from Old World and New World primates. J Virol 79: 3930-3937. (Pubitemid 40388333)
43. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5a. Proc Natl Acad Sci U S A 101: 10774-10779. (Pubitemid 38955818)
44. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650. (Pubitemid 34886867)
45. Zheng Y-H, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78: 6073-6076. (Pubitemid 38661697)
46. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23: 2451-2458. (Pubitemid 38954852)
47. Baumann JG (2006) Intracellular restriction factors in mammalian cells - an ancient defense system finds a modern foe. Curr HIV Res 4: 141-168.
48. Schröfelbauer B, Chen D, Landau NR (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (vif). Proc Natl Acad Sci U S A 101: 3927-3932. (Pubitemid 38381079)
49. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, et al. (2004) A single amino acid substitution in the human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 101: 5652-5657. (Pubitemid 38481211)
50. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A 101: 3770-3774. (Pubitemid 38381053)
51. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, et al. (2009) Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5: 1-12. doi:10.1371/journal.ppat. 1000300.
52. Goffinet C, Allespach I, Homann S, Tervo H-M, Habermann A, et al. (2009) HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5: 285-297.
53. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, et al. (1999) Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 73: 2343-2349. (Pubitemid 29098139)
54. Zheng Y-H, Plemenitas A, Fielding CJ, Peterlin BM (2003) Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A 100: 8460-8465. (Pubitemid 36842567)
55. Sinclair E, Barbosa P, Feinberg MB (1997) The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable. J Virol 71: 3641-3651. (Pubitemid 27172376)
56. Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, et al. (1994) Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intract nef gene. J Virol 68: 2906-2914. (Pubitemid 24129738)
57. Chowers MY, Pandori MW, Spina CA, Richman DD, Guatelli JC (1995) The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212: 451-457.
58. Aiken C, Trono D (1995) Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 69: 5048-5056.
59. Pizzato M, Helander A, Popova E, Calistri A, Zamborlini A, et al. (2007) Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A 104: 6812-6817. (Pubitemid 47175583)
60. Roeth JF, Collins KL (2006) Human immunodeficiency virus type 1 Nef: Adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev 70: 548-563. (Pubitemid 43895037)
61. Paul M, Mazumder S, Raja N, Jabbar MA (1998) Mutational analysis of the human immunodeficiency virus type 1 vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells. J Virol 72: 1270-1279. (Pubitemid 28116912)
62. Tiganos E, Friborg J, Allain B, Daniel NG, Yao X-J, et al. (1998) Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 vpu protein. Virology 251: 96-107. (Pubitemid 28527722)
63. Schubert U, Bour S, Ferrer-Montiel AV, Montal M, Maldarelli F, et al. (1996) The two biological activities of human immunodeficiency virus type 1 vpu protein involve separable structural domains. J Virol 70: 809-819. (Pubitemid 26028996)
64. Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, et al. (1995) Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cel growth. Genomics 26: 527-534.
65. The Chimpanzee Sequencing and Analysis Consortium (2005) Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 437: 69-87.
66. Wang J-K, Kiyokawa E, Verdin E, Trono D (2000) The nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A 97: 394-399. (Pubitemid 30055842)
67. Zheng YH, Plemenitas A, Linnemann T, Fackler OT, Peterlin BM (2001) Nef increases infectivity of HIV via lipid rafts. Curr Biol 11: 875-879. (Pubitemid 32532814)
68. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, et al. (1991) Importance of the nef gene for maintenance of high virus loads and for the development of AIDS. Cell 65: 651-662.
69. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AYM, et al. (1998) Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 72: 1431-1437. (Pubitemid 28116930)
70. Benson RE, Sanfridson A, Ottinger JS, Doyle C, Cullen BR (1993) Downregulation of cell-surface CD4 expression by simian immunodeficiency virus nef prevents viral super infection. J Exp Med 177: 1561-1566. (Pubitemid 23146122)
71. DeGottardi MQ, Specht A, Metcalf B, Kaur A, Kirchhoff F, et al. (2008) Selective downregulation of rhesus macaque and sooty mangabey major histocompatibility complex class I molecules by nef alleles of simian immunodeficiency virus and human immunodeficiency virus type 2. J Virol 82: 3139-3146. (Pubitemid 351329203)
72. Alexander L, Du Z, Rosenzweig M, Jung JU, Desrosiers RC (1997) A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J Virol 71: 6094-6099. (Pubitemid 27304950)
73. Alexander L, Du Z, Howe AYM, Czajak S, Desrosiers RC (1999) Induction of AIDS in rhesus monkeys by a recombinant simian immunodeficiency virus expressing nef of human immunodeficiency virus type 1. J Virol 73: 5814-5825. (Pubitemid 29274868)
74. VanDamme N, Guatelli J (2008) HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes. Cell Microbiol 10: 1040-1057.
75. Hatziioannou T, Princiotta M, Piatak M, Yuan F, Zhang F, et al. (2006) Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314: 95. (Pubitemid 44547747)
76. Kamada K, Igarashi T, Martin MA, Khamsri B, Hatcho K, et al. (2006) Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A 103: 16959-16964. (Pubitemid 44737360)
77. Igarashi T, Iyengar R, Byrum RA, Buckler-White A, Dewar RL, et al. (2007) Human immunodeficency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J Virol 81: 11549-11552. (Pubitemid 47536127)
78. Hatziioannou T, Ambrose Z, Chung NPY, Piatak M Jr, Yuan F, et al. (2009) A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A 106: 4425-4429.
79. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59. (Pubitemid 19125653)
80. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, et al. (1990) Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248: 1109-1112. (Pubitemid 20189864)
81. Regier DA, Desrosiers RC (1990) The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses 6: 1221-1231.
82. Jia B, Ng SK, DeGottardi MQ, Piatak M, Yuste E, et al. (2009) Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIVmac239. PLoS Pathog 5: 1-19. doi:10.1371/journal. ppat.1000272.
83. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency virus syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284-291. (Pubitemid 16013975)
84. Fisher AG, Collati E, Ratner L, Gallo RC, Wong-Staal F (1985) A molecular clone of HTLV-III with biological activity. Nature 316: 262-265. (Pubitemid 15073693)
85. Ratner L, Fisher A, Jagodzinski LL, Mitsuya H, Liou R-S, et al. (1987) Complete nucleotide sequences of functional clones of AIDS virus. AIDS Res Hum Retroviruses 3: 57-69. (Pubitemid 17144024)
86. Swigut T, Iafrate AJ, Muench J, Kirchhoff F, Skowronski J (2000) Simian and human immunodeficiency virus nef proteins use different surfaces to downregulate class I major histocompatibility complex antigen expression. J Virol 74: 5691-5701. (Pubitemid 30346604)
87. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, et al. (2006) Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125: 1055-1067. (Pubitemid 43884762)
88. Nguyen K-L, Liano M, Akari H, Miyagi E, Poeschla EM, et al. (2004) Codon optimization of the HIV-1 vpu and vif genes stabilizes their messenger RNA and allows for highly efficient Rev-independent expression. Virology 319: 163-175. (Pubitemid 38251258)
89. Rosati M, Gegerfelt Av, Roth P, Alicea C, Valentin A, et al. (2005) DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 79: 8480-8492. (Pubitemid 40853549)
90. Chackerian B, Haigwood NL, Overbaugh J (1995) Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology 213: 386-394.